NDA 021730 · Lupin
Xopenex Hfa
Levalbuterol Tartrate · Inhalation
Last checked: Nov 20, 2026Latest source record: Feb 27, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Mar 11, 2005
Approved uses
2
Original approval plus efficacy supplements
Registered trials
793
238 Phase 3, 24 recruiting
FAERS reports
3,733
1,628 serious, 129 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 2, 2025.
XOPENEX HFA is a beta 2 -adrenergic agonist indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ( 1.1 ) 1.1 Bronchospasm XOPENEX HFA is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.
Mechanism: Activation of beta 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cyclic AMP). The increase in cyclic AMP is associated with the activation of protein kinase A, which in turn, inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in muscle relaxation. Levalbuterol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Increased cyclic AMP concentrations are also...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 12, 2015 Supplement 36 · Efficacy Pediatric Clinical Pharmacology ReviewPediatric Medical ReviewPediatric Statistical Review
- Mar 11, 2005 Original approval · Type 3 - New Dosage Form LetterReviewLabel
1 products under this application
- XOPENEX HFA · LEVALBUTEROL TARTRATE EQ 0.045MG BASE/INH · AEROSOL, METERED, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Levalbuterol" as an intervention, any sponsor and status, largest first.
GlaxoSmithKlineGSK (GSK)
NCT01475721 · 11,751 participants · Start Nov 18, 2011 · Primary completion Jun 23, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 4 more · For: Asthma
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 808 sites in all
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01471340 · 11,744 participants · Start Jan 9, 2012 · Primary completion Nov 30, 2016
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg and 4 more · For: Asthma
- Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00563381 · 7,376 participants · Start Jan 2008 · Primary completion Apr 2010
Drug: Tiotropium bromide; Salmeterol and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Feldbach, Austria; Feldkirch, Austria; Gänserndorf, Austria · 752 sites in all
- 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01462344 · 6,250 participants · Start Nov 17, 2011 · Primary completion Nov 1, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 2 more · For: Asthma
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 530 sites in all
- Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00268216 · 6,228 participants · Start Sep 2000 · Primary completion Nov 2005
Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Jasper, Alabama; Mobile, Alabama · 459 sites in all
- Individualizing Treatment for Asthma in Primary Care (Full Study)Pivotal-lookingRecruiting
DARTNet InstituteGovernment (non-federal)
NCT07052942 · 3,200 participants (planned) · Start Aug 1, 2025 · Primary completion Nov 15, 2029
Drug: Inhaled corticosteroid (ICS); Azithromycin · For: Asthma; Asthma Attack; Asthma Exacerbations
Sites: Aurora, Colorado; Orlando, Florida; Kansas City, Kansas · 13 sites in all
- A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With AsthmaPivotal-lookingCompleted
Bond Avillion 2 Development LPIndustry
NCT03769090 · 3,132 participants · Start Dec 13, 2018 · Primary completion Aug 19, 2021
Drug: Albuterol sulfate metered-dose inhaler 180 μg · For: Asthma
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 345 sites in all
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02571777 · 3,092 participants · Start Dec 8, 2015 · Primary completion Jun 14, 2019
Drug: QVM149 150/50/160; QVM149 150/50/80 and 3 more · For: Asthma
Sites: Bahía Blanca, Argentina; CABA, Argentina; Florida, Argentina · 403 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- device delivery system issue642
- drug dose omission by device556
- no adverse event510
- dyspnoea440
- headache244
- nausea229
- fatigue225
- cough213
- asthma210
- off label use197
- dizziness174
- pneumonia172
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 7 |
| 2007 | 24 |
| 2008 | 45 |
| 2009 | 33 |
| 2010 | 28 |
| 2011 | 42 |
| 2012 | 78 |
| 2013 | 78 |
| 2014 | 92 |
| 2015 | 141 |
| 2016 | 294 |
| 2017 | 190 |
| 2018 | 167 |
| 2019 | 190 |
| 2020 | 210 |
| 2021 | 145 |
| 2022 | 178 |
| 2023 | 358 |
| 2024 | 471 |
| 2025 | 545 |
| 2026 | 417 |
Recalls
2 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xopenex HFA (Levalbuterol Tartrate)
2024 spending
$1.5M
Beneficiaries
6,461
15,310 claims
Per beneficiary
$232
$4.57 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $141,407 |
| 2024 | $1,496,738 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children.
Hardasmalani MD, DeBari V, Bithoney WG, et al. · Pediatr Emerg Care 2005 · Comparative Study, Randomized Controlled Trial
- High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial.
Andrews T, McGintee E, Mittal MK, et al. · J Pediatr 2009 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis.
Jat KR, Khairwa A · Pulm Pharmacol Ther 2013 · Comparative Study, Meta-Analysis
- Randomized placebo controlled assessment of airway inflammation due to racemic albuterol and levalbuterol via exhaled nitric oxide testing.
Freiler JF, Arora R, Kelley TC, et al. · Int J Chron Obstruct Pulmon Dis 2006 · Randomized Controlled Trial
- Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial.
Ralston ME, Euwema MS, Knecht KR, et al. · J Emerg Med 2005 · Clinical Trial, Comparative Study
- A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults.
Nowak R, Emerman C, Hanrahan JP, et al. · Am J Emerg Med 2006 · Comparative Study, Multicenter Study
Sponsor: Lupin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.